BioLamina AB

Private

SundbybergHealthcare & Life Scienceshttps://biolamina.com/

Last Round

Debt

Apr 17, 2026

Total Funding Raised

$23.59M

Company Overview

BioLamina AB is a biotechnology company that develops, manufactures, and commercializes human recombinant laminin substrates for cell culture research and therapeutic applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

recombinant human lamininstem cell cultureextracellular matrixcell therapy manufacturingregenerative medicineanimal-origin-freebiomaterialsorganoid developmentcell culture reagentslab reagentsstem cell mediaclinical-grade substratescell culture matrixbiotech supply chain

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BioLamina AB Comps

Public and private peers based on sector, stage, and business model.

BioLamina AB comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

BioLamina AB Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Debt	Apr 17, 2026
VC Round	Sep 12, 2023

View all Funding Rounds

Key People

Founding team and executive leadership

Brian Hawkins

Chief Technology Officer

Executive Team

Magnus Åkerhielm

Chief Financial Officer

Executive Team

Ulrika Ljungkvist

Chief Operating Officer

Executive Team

BioLamina AB Investors

Notable investors and investment history

BioLamina AB investors
Investor	Rounds
Lauxera Capital Partners	VC Round
European Investment Bank Group	Debt
Northislet AB	VC Round

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

May 3, 2025
Monthly visitors grew 97% MoM, reaching 6.9K.

View all signals

BioLamina AB Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

BioLamina AB Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BioLamina AB's valuation, stock price, and market status.

Firmographic Details

HeadquartersSundbyberg

Employee Range120

Year Founded2009

Last FundingApr 17, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.